Skip to main content

Table 7 MMP content and levels of T cell subsets before and after treatment in patients with different subtypes of lung cancer in the test group

From: Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer

Project

SCLC

NSCLC

P Value

LADC

LSCC

P Value

Before treatment

 MMP-2 (ng/L)

182.93 ± 12.24

181.52 ± 11.67

0.48

180.22 ± 10.37

181.05 ± 12.14

0.65

 MMP-9 (ng/L)

206.17 ± 21.43

207.88 ± 21.86

0.64

207.61 ± 21.59

208.20 ± 21.54

0.87

 CD4+%

33.63 ± 3.76

33.00 ± 4.09

0.36

32.55 ± 3.64

33.17 ± 3.93

0.32

 CD8+%

30.87 ± 3.03

30.46 ± 3.34

0.46

30.25 ± 3.13

30.77 ± 3.03

0.31

 CD4+/CD8+

1.20 ± 0.22

1.15 ± 0.23

0.20

1.17 ± 0.21

1.13 ± 0.21

0.25

After treatment

 MMP-2 (ng/L)

35.6 ± 1.02

30.52 ± 2.12

< 0.0001

30.71 ± 2.31

30.78 ± 1.86

0.85

 MMP-9 (ng/L)

35.37 ± 1.25

31.08 ± 1.52

< 0.0001

31.13 ± 1.47

30.86 ± 1.3

0.25

 CD4+%

38.15 ± 4.97

37.78 ± 5.08

0.66

37.33 ± 4.63

37.81 ± 5.05

0.54

 CD8+%

27.22 ± 3.66

26.93 ± 3.71

0.64

26.51 ± 3.29

27.13 ± 3.51

0.27

 CD4+/CD8+

1.36 ± 0.18

1.33 ± 0.21

0.39

1.30 ± 0.18

1.34 ± 0.20

0.20